PRKDC and acute myeloid leukemia: Akt, a well-known component of the PI3-kinase/Akt/mTOR signaling network, is also a therapeutic target in acute myelogenous leukemia patients and seems to play a role in the phosphorylation of DNA-PK and improving the efficiency of repair [189].